share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

Recursion Pharmaceuticals | 4：持股變動聲明-董事 Borgeson Blake
美股sec公告 ·  06/05 18:17
Moomoo AI 已提取核心訊息
Recursion Pharmaceuticals, Inc. (RXRX) reported that Blake Borgeson, a key figure at the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Borgeson's direct holdings in the company have increased to a total of 7,200,010 shares of Common Stock.
Recursion Pharmaceuticals, Inc. (RXRX) reported that Blake Borgeson, a key figure at the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Borgeson's direct holdings in the company have increased to a total of 7,200,010 shares of Common Stock.
Recursion Pharmaceuticals，Inc.（RXRX）報告，公司重要人物Blake Borgeson於2024年6月3日獲授予13,097股A類普通股。這筆交易於同一天完成，交易價格為每股0.00美元，表明這些股票很可能是作為補償計劃或激勵計劃的一部分授予的。此交易後，Borgeson在公司的直接持股共增加到7,200,010股普通股。
Recursion Pharmaceuticals，Inc.（RXRX）報告，公司重要人物Blake Borgeson於2024年6月3日獲授予13,097股A類普通股。這筆交易於同一天完成，交易價格為每股0.00美元，表明這些股票很可能是作為補償計劃或激勵計劃的一部分授予的。此交易後，Borgeson在公司的直接持股共增加到7,200,010股普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息